对氟苯乙酰肼 | 34547-28-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 对氟苯乙酰肼
• 中文别名: 4-氟苯乙酰肼
• 英文名称: 2-(4-fluorophenyl)acetohydrazide
• 英文别名: 2-(4-fluorophenyl)acetic hydrazide
• CAS: 34547-28-9
• 化学式: C₈H₉FN₂O
• mdl: MFCD06655053
• 分子量: 168.171
• InChiKey: PFBNINAURUGQRR-UHFFFAOYSA-N

物化性质

• 沸点：
  370.6±25.0 °C(Predicted)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2928000090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  -20°C下，应避光保存在惰性气体中。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Fluorophenylacetic Acid Hydrazide
: CVT00035
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 168,17 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Fluorophenylacetic Acid Hydrazide
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Fluorophenylacetic Acid Hydrazide
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用作医药中间体

反应信息

• 作为反应物：
  描述：

  对氟苯乙酰肼 在 palladium 10% on activated carbon oxone 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 DMF (N,N-dimethyl-formamide) 、 水 、 乙酸乙酯 、 甲苯 、 乙腈 为溶剂， 反应 25.5h， 生成 1-cyclohexyl-5-[5-(4-fluorobenzyl)-[1,3,4]-oxadiazol-2-yl]-2-(pyridin-3-yl)-1H-benzimidazole
  参考文献：
  名称：

  [EN] FUSED HETEROCYCLIC COMPOUND HAVING ANTI-HCV EFFECT
  [FR] COMPOSÉ HÉTÉROCYCLIQUE FONDU AYANT UN EFFET ANTI-VHC

  摘要：

  【化１】（其中，A为N或CH；Het为以下任一基团：【化２】R0和R为氢、可取代的烷基、可取代的环烷基、可取代的芳基等；R1和R2为氢、可取代的烷基、可取代的烯基、可取代的环烷基、可取代的芳基、可取代的杂环芳基等；p为0~3的整数，R3为可取代的烷基等）所示化合物，其药学上可接受的盐，或它们的溶剂结晶物。

  公开号：

  WO2005121132A1
• 作为产物：
  描述：

  对氟苯乙酰氯 在 一水合肼 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以86%的产率得到对氟苯乙酰肼
  参考文献：
  名称：

  Synthesis, Crystal Structure, Anti-inflammatory and Anti-hyperglycemic Activities of Novel 3,4-Disubstituted 1,2,4-Triazol-5(4H)-one Derivatives

  摘要：

  合成了一系列3,4-二取代1,2,4-三唑-5(4H)-酮5a-r，具有不同的甲氧基苯基、氟苯基、甲苯基和苯基。该化合物通过将肼类羧酰胺4a-r在2N氢氧化钠溶液中回流脱氢环化而制备而成。肼类羧酰胺4a-r是通过相应芳香烃羧酸肼的缩合反应与氟、甲苯和甲氧基苯异氰酸酯合成的。新合成的化合物（5ar）通过红外光谱、1H NMR和13C NMR进行表征。其中一种化合物5a的结构通过单晶X射线衍射分析确定。所有合成的化合物均被筛选用于抗炎和抗糖尿病（α-葡萄糖苷酶和α-淀粉酶抑制）活性，以识别可能用于预防与糖尿病和炎症相关的损伤的新药物。化合物5j、5k和5m以剂量依赖的方式降低II型胶原蛋白的表达；同样，5l以剂量依赖的方式降低兔关节软骨细胞中的COX-2表达，具有很强的抗炎潜力，而一些衍生物包括5c、5e、5g和5h则引起炎症。同时，与参比标准阿卡波糖相比，化合物5b、5f、5k和5q表现出优秀的α-葡萄糖苷酶和中等α-淀粉酶抑制特性，而化合物5g、5h、5i、5j、5l和5o在这一系列中显示出中等到低的酶抑制潜力。

  DOI：

  10.2174/1573406410666140327142912

文献信息

• Design, synthesis, insecticidal activity and 3D-QSR study for novel trifluoromethyl pyridine derivatives containing an 1,3,4-oxadiazole moiety
  作者：F. Z. Xu、Y. Y. Wang、D. X. Luo、G. Yu、S. X. Guo、H. Fu、Y. H. Zhao、J. Wu

  DOI：10.1039/c8ra00161h

  日期：——

  A series of trifluoromethyl pyridine derivatives containing 1,3,4-oxadiazole moiety was designed, synthesized and bio-assayed for their insecticidal activity. The result of bio-assays indicated the synthesized compounds exhibited good insecticidal activity against Mythimna separata and Plutella xylostella, most of the title compounds show 100% insecticidal activity at 500 mg L−1 and >80% activity at

  设计、合成了一系列含有1,3,4-恶二唑部分的三氟甲基吡啶衍生物，并对其杀虫活性进行了生物测定。生物测定结果表明，合成的化合物对Mythimna separata和Plutella xylostella表现出良好的杀虫活性，大多数标题化合物在 500 mg L -1 时表现出 100% 的杀虫活性，在250 mg L -1时表现出大于 80% 的杀虫活性。两种害虫。化合物E18和E27对Mythimna separata的LC 50值分别为38.5和30.8 mg L -1，接近阿维菌素（29.6 mg L -1); 化合物E5、E6、E9、E10、E15、E25、E26和E27在 250 mg L -1下显示出 100% 的活性，优于毒死蜱 (87%)。提出了具有良好可预测性的 CoMFA 和 CoMSIA 模型，表明苯环 2 位和 4 位具有适当体积的吸电子基团可以增强杀虫活性。
• Xanthenone-based hydrazones as potent α-glucosidase inhibitors: Synthesis, solid state self-assembly and in silico studies
  作者：Qamar-un-Nisa Tariq、Sana Malik、Ajmal Khan、Muhammad Moazzam Naseer、Shafi Ullah Khan、Abida Ashraf、Muhammad Ashraf、Muhammad Rafiq、Khalid Mahmood、Muhammad Nawaz Tahir、Zahid Shafiq

  DOI：10.1016/j.bioorg.2018.11.053

  日期：2019.3

  The pharmacological properties of molecules are also calculated by MedChem Designer which determines the ADME (absorption, distribution, metabolism, excretion) properties of molecules. The solid state self-assembly of compound 5g is discussed to show the conformation and role of iminoamide moiety in the molecular packing.

  基于黄酮的衍生物（5a-n）已被合成为潜在的α-葡萄糖苷酶抑制剂。所有合成的化合物（5a-n）都具有FTIR，1H NMR，13C NMR和HRMS的特征，在5g的情况下，也可以通过X射线晶体学技术表征。与标准阿卡波糖（IC50 = 375.38±0.12 µM）相比，这些化合物具有不同程度的α-葡萄糖苷酶抑制活性。在该系列中，具有三氟甲基苯基的化合物5l（IC50 = 62.25±0.11 µM）被发现是活性最高的化合物。进行分子建模以建立更具活性的化合物5l的结合模式，这揭示了取代模式的重要性。分子的药理特性也由MedChem Designer计算得出，它决定了ADME（吸收，分布，代谢，排泄）的性质。讨论了化合物5g的固态自组装，以显示亚氨基酰胺部分在分子包装中的构象和作用。
• Synthesis and Biological Activity of Anthranilic Diamide Derivatives Incorporating 1,3,4-oxadiazole or Nitrogen-containing Saturated Heterocyclic Moieties
  作者：Wen-Juan Zhou、Li Zhang、Wei Xiao、He-Ju Chen、Wen-Neng Wu、Gui-Ping Ouyang

  DOI：10.1002/jhet.2724

  日期：2017.3

  novel anthranilic diamide derivatives incorporating 1,3,4‐oxadiazole or nitrogen‐containing saturated heterocyclic moieties were synthesized, characterized, and evaluated for bacteriostatic activity against three phytopathogenic bacteria Xanthomonas oryzae pv. Oryzae (Xoo), Xanthomonas axonopodis pv. Citri (Xac), Ralstonia solanacearum (R. solanacearum). The preliminary biological results indicated that

  合成，表征并评估了一系列新的结合1,3,4-恶二唑或含氮饱和杂环部分的邻氨基苯甲酰胺衍生物对三种植物病原菌米氏黄单胞菌（Panthomonas oryzae pv）的抑菌活性。Oryzae（Xoo），Xanthomonas axonopodis pv。柠檬（Xac），青枯雷尔氏菌（R. solanacearum）。初步的生物学结果表明，大多数化合物对三种植物病原菌均具有抑菌活性。在这些化合物中，化合物6g，6f和6i表现出更好的抗菌活性。在浓度为200 µg / mL的测试中，化合物6i和6j的抗菌活性是96％。特别地，化合物6h表现出的针对Xoo的抑菌活性类似于商业药物比美噻唑表现出的抑菌活性。
• Expedient discovery for novel antifungal leads: 1,3,4-Oxadiazole derivatives bearing a quinazolin-4(3H)-one fragment
  作者：Xiaobin Wang、Jianqi Chai、Xiangyi Kong、Fei Jin、Min Chen、Chunlong Yang、Wei Xue

  DOI：10.1016/j.bmc.2021.116330

  日期：2021.9

  Developing novel fungicide candidates are intensively promoted by the rapid emergences of resistant fungi that outbreak on agricultural production. Aiming to discovery novel antifungal leads, a series of 1,3,4-oxadiazole derivatives bearing a quinazolin-4(3H)-one fragment were constructed for evaluating their inhibition effects against phytopathogenic fungi in vitro and in vivo. Systematically structural

  农业生产中爆发的抗性真菌的迅速出现，极大地促进了新型杀菌剂候选物的开发。为了发现新的抗真菌先导物，构建了一系列带有 quinazolin-4(3 H )-one 片段的 1,3,4-恶二唑衍生物，用于评估它们在体外和体内对植物病原真菌的抑制作用。生成系统的结构的优化的生物活性分子余32所识别作为对有希望的抑制剂纹枯病与体内200 μg/mL 时的预防效果为 58.63%。扫描电镜和透射电镜观察表明，生物活性分子I 32可以诱导菌丝的蔓延生长、菌丝表面的局部收缩和破裂、液泡的极度膨胀、细胞壁的显着变形、以及线粒体数量的减少。上述结果为发现带有喹唑啉-4(3 H )-one 和1,3,4-恶二唑片段的抗真菌先导物提供了不可或缺的补充。
• MODULATORS FOR AMYLOID BETA
  申请人：Baumann Karlheinz

  公开号：US20090215759A1

  公开（公告）日：2009-08-27

  The invention relates to compounds of formula wherein the substituents are as described in claim 1 . Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  该发明涉及以下式的化合物 其中取代基如权利要求中所述 。式I的化合物是淀粉样蛋白β的调节剂，因此它们可能对治疗或预防与大脑中β-淀粉样蛋白沉积相关的疾病有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病变，遗传性脑出血伴淀粉样变性，荷兰型（HCHWA-D），多梗死性痴呆，拳击性痴呆和唐氏综合征。